Chris Viehbacher, Biogen CEO (Sarah Merians Photography for Endpoints News)
May 1, 2025 07:35 AM EDTUpdated 01:04 PM
Pharma

Bio­gen says Leqem­bi sales are im­prov­ing slow­ly fol­low­ing lack­lus­ter launch

Ayisha Sharma

News Reporter

Bio­gen said sales of its Ei­sai-part­nered Alzheimer’s drug Leqem­bi crept close to the $100 mil­lion mark in the first three months of the year, af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

US drug­mak­ers in­creas­ing­ly look abroad for clin­i­cal tri­als as con­fi­dence in FDA wa­vers

Lil­ly meets sales ex­pec­ta­tions, but No­vo gains on PBM win

Ex­clu­sive: Ex-Cal­i­co sci­en­tist launch­es State­ly Bio with new way to study cells

Af­ter hunt for al­ter­na­tives, Kro­nos Bio se­lects Tang Cap­i­tal's Con­cen­tra for a deal

Arv­inas ends plans for two Phase 3 breast can­cer tri­als; Phath­om makes cuts

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times